Skip to main content

Table 1 Baseline characteristics of the population included before (n = 9129) and after (n = 5810) propensity score matching: socio-demographics, comorbidities, laboratory determinations, comedications

From: Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database

Variables Before PS-matching After PS-matching
N (%) Cilostazol (n = 3345) Pentoxifylline (n = 5784) p-value Cilostazol (n = 2905) Pentoxifylline (n = 2905) p-value
Gender
 Women 711(21.3) 2444 (42.3) 0.001 695 (23.9) 676 (23.3) 0.557
 Men 2634 (78.7) 3340 (57.7)   2210 (76.1) 2229 (76.7)  
Mean age (SD) 68.5 (11.3) 70.1 (13.4) 0.001 68.8 (11.4) 69.4 (12.2) 0.058
PAD coded 1394 (41.7) 968 (16.7) 0.001 985 (33.9) 918 (31.6) 0.061
ABPI
 < 0.7 195 (5.8) 214 (3.7) 0.001 156 (5.4) 146 (5.0) 0.359
 ≥ 0.7 151 (4.5) 248 (4.3)   132 (4.5) 154 (5.3)  
 Missing 2999 (89.7) 5322 (92.0)   2617 (90.1) 2605 (89.7)  
Smoking status
 Non-smoker 1037 (31.0) 2666 (46.1) 0.001 955 (32.9) 1102 (37.9) < 0.001
 Smoker 1057 (31.6) 1085 (18.8)   869 (29.9) 725 (25.0)  
 Ex-smoker 944 (28.2) 1157 (20.0)   792 (27.3) 760 (26.2)  
 Missing 307 (9.2) 876 (15.1)   289 (9.9) 318 (10.9)  
BMI, kg/m2, mean (SD) 28.3 (4.3) 28.7 (5.0) 0.017 28.4 (4.4) 28.5 (4.7) 0.505
 < 25 295 (8.8) 482 (8.3) 0.001 253 (8.7) 271 (9.3)  
 25–30 712 (21.3) 913 (15.8)   603 (20.8) 538 (18.5)  
 > 30 438 (13.1) 789 (13.6)   382 (13.1) 419 (14.4)  
 Missing 1900 (56.8) 3600 (62.2)   1667 (57.4) 1677 (57.7)  
Hypertension 2059 (61.6) 3396 (58.7) 0.008 1794 (61.8) 1811 (62.3) 0.646
Type 2 DM 1296 (38.7) 1876 (32.4) 0.001 1112 (38.3) 1120 (38.6) 0.829
Dyslipidemia 1531 (45.8) 2227 (38.5) 0.001 1271 (43.8) 1285 (44.2) 0.711
CAD 533 (15.9) 803 (13.9) 0.008 461 (15.9) 461 (15.9) 1
AF 152 (4.5) 457 (7.9) 0.001 145 (5.0) 177 (6.1) 0.067
Other arrhythmias 20 (0.6) 39 (0.7) 0.661 15 (0.5) 23 (0.8) 0.193
Prior stroke 313 (9.4) 506 (8.7) 0.327 268 (9.2) 286 (9.8) 0.421
Cerebral haemorrhage 10 (0.3) 24 (0.4) 0.381 10 (0.3) 6 (0.2) 0.317
Digestive haemorrhage 63 (1.9) 123 (2.1) 0.428 31 (1.1) 25 (0.9) 0.420
Other haemorrhages 81 (2.5) 160 (4.2) 0.323 75 (2.6) 74 (2.5) 0.934
BP
 Bad control (≥140/90 mmHg) 1117 (33.4) 1605 (27.7) 0.001 954 (32.8) 880 (30.3) 0.041
 Systolic BP, mean (SD) 137.9 (15.6) 135.9 (15.3) 0.001 137.9 (15.6) 136.2 (14.9) < 0.001
 Diastolic BP, mean (SD) 74.7 (9.3) 74.5 (8.9) 0.347 74.7 (9.3) 74.5 (9.0) 0.405
Total
cholesterol, mg/dL, mean (SD) 193.3 (42.2) 194.8 (41.5) 0.269 194.0 (42.1) 193.6 (42.8) 0.801
LDL cholesterol, mg/dL, mean (SD) 116.8 (36.4) 117.8 (35.4) 0.440 117.3 (36.4) 115.9 (35.8) 0.346
 ≤ 100 479 (34.3) 688 (31.8) 0.119 401 (33.9) 407 (34.4) 0.068
 > 100 916 (65.7) 1474 (68.2)   783 (66.1) 777 (65.6)  
 ≤ 150 1135 (81.4) 1764 (81.6) 0.864 960 (81.1) 979 (82.7) 0.311
 > 150 260 (18.6) 398 (18.4)   224 (18.9) 205 (17.3)  
eGFR (MDRD), mL/min/1.73m2
 ≤ 30 30 (0.9) 83 (1.4) 0.001 27 (0.9) 31 (1.1) 0.728
 30–59 387(11.6) 754 (13.0)   352 (12.1) 374 (12.9)  
 ≥ 60 1222 (36.5) 1854 (32.1)   1021 (35.1) 1027 (35.4)  
 Missing 1706 (51.0) 3093 (53.5)   1505 (51.8) 1473 (50.7)  
Diuretics 863 (25.8) 1905 (32.9) < 0.001 796 (27.4) 813 (28.0) 0.618
β-blockers 625 (18.7) 1082 (18.7) 0.979 560 (19.3) 546 (18.8) 0.640
Calcium channel antagonists 721 (21.6) 1216 (21.0) 0.550 639 (22.0) 635 (21.9) 0.899
ACEI* 1288 (38.5) 1931 (33.4) 0.001 1102 (37.9) 1092 (37.6) 0.787
ARB* 949 (28.4) 1444 (25.0) 0.001 833 (28.7) 857 (29.5) 0.488
Vasodilators 397 (11.9) 779 (13.5) 0.028 360 (12.4) 372 (12.8) 0.635
Lipid modifying agents 2077 (62.1) 2652 (45.9) 0.001 1716 (59.1) 1698 (58.5) 0.631
Antidiabetic drugs and insulins 1275 (38.1) 1793 (31.0) < 0.001 1104 (38.0) 1079 (37.1) 0.498
Proton pump inhibitors 1967 (58.8) 3541 (61.2) 0.023 1724 (59.3) 1759 (60.6) 0.349
NSAID* 1233 (36.9) 2290 (39.6) 0.010 1085 (37.3) 1094 (37.7) 0.807
OAC* 342 (10.2) 696 (12.0) 0.009 301 (10.4) 311 (10.7) 0.669
Antiplatelets 2169 (64.8) 2740 (47.4) 0.001 1797 (61.9) 1776 (61.1) 0.571
  1. * PS propensity score, SD standard deviation, PAD peripheral artery disease, ABPI ankle-brachial pressure index, BMI body mass index, DM diabetes mellitus, CAD coronary artery disease, AF atrial fibrillation, BP blood pressure, eGFR estimated glomerular filtrate rate, MDRD modification of diet in renal disease formula, ACEI angiotensin-converter enzyme inhibitors, ARB angiotensin-receptor blockers, NSAID non-steroidal anti-inflammatory drugs, OAC oral anticoagulants
  2. ** ABPI, mean value in the last 6 months. BP, mean values in the last year. Cholesterol measures, last value in prior 6 months. eGFR, mean value in the last 6 months. Co-medications, 6 months prior to inclusion